VANGUARD GROUP INC - BELLICUM PHARMACEUTICALS INC ownership

BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 98 filers reported holding BELLICUM PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 4.09 and the average weighting 0.1%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of BELLICUM PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2019$2,295,000
+22.9%
1,778,9260.0%0.00%
Q3 2019$1,868,000
-41.5%
1,778,926
-5.2%
0.00%
Q2 2019$3,191,000
-57.6%
1,877,331
-15.9%
0.00%
Q1 2019$7,519,000
+31.7%
2,231,079
+14.1%
0.00%
Q4 2018$5,711,000
-52.4%
1,956,217
+0.4%
0.00%
Q3 2018$11,999,000
-15.5%
1,947,842
+1.2%
0.00%
-100.0%
Q2 2018$14,202,000
+60.5%
1,924,432
+42.6%
0.00%
Q1 2018$8,851,000
-22.7%
1,349,300
-0.9%
0.00%
-100.0%
Q4 2017$11,448,000
-18.2%
1,361,357
+12.3%
0.00%0.0%
Q3 2017$14,003,000
-0.6%
1,212,275
+0.5%
0.00%0.0%
Q2 2017$14,092,000
+7.6%
1,206,436
+13.6%
0.00%0.0%
Q1 2017$13,100,000
+6.7%
1,061,582
+17.8%
0.00%0.0%
Q4 2016$12,278,000
-29.5%
901,431
+3.0%
0.00%0.0%
Q3 2016$17,414,000
+78.8%
875,053
+16.4%
0.00%0.0%
Q2 2016$9,740,000
+51.6%
751,584
+9.4%
0.00%
Q1 2016$6,425,000
-51.7%
687,239
+4.8%
0.00%
-100.0%
Q4 2015$13,290,000
-93.1%
655,682
-88.6%
0.00%
-85.7%
Q3 2015$191,463,000
+3113.0%
5,744,009
+1950.3%
0.01%
Q2 2015$5,959,000
+17.3%
280,148
+27.8%
0.00%
Q1 2015$5,078,000
+239.0%
219,167
+237.2%
0.00%
Q4 2014$1,498,00065,0000.00%
Other shareholders
BELLICUM PHARMACEUTICALS INC shareholders Q1 2017
NameSharesValueWeighting ↓
Avoro Capital Advisors LLC 220,000$5,069,0003.43%
Perceptive Advisors 1,046,402$24,109,0002.02%
Redmile Group, LLC 860,809$17,269,0001.88%
Baker Brothers Advisors 4,283,732$98,697,0001.01%
RA Capital Management 1,026,402$9,337,0001.00%
Ghost Tree Capital, LLC 75,000$1,728,0000.83%
ACUTA CAPITAL PARTNERS, LLC 45,750$1,054,0000.71%
GREAT POINT PARTNERS LLC 50,000$1,152,0000.55%
EMERALD MUTUAL FUND ADVISERS TRUST 167,210$3,853,0000.33%
EMERALD ADVISERS, LLC 198,202$4,567,0000.24%
View complete list of BELLICUM PHARMACEUTICALS INC shareholders